Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia

Pediatrics International

Volumn 51, Issue 1, 2009, Pages 25-32

  Neelakantan, Srividya ^a   Widness, John A ^b   Schmidt, Robert L ^b   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Anemia of prematurity; Erythropoietin; Pharmacokinetic pharmacodynamic analysis; Progenitor activation; Reticulocyte

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ERYTHROID PRECURSOR CELL; NEWBORN ANEMIA; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; RETICULOCYTE;

ANEMIA, NEONATAL; ANIMALS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INFANT, NEWBORN; PILOT PROJECTS; SHEEP;

EID: 60849097601     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2008.02648.x     Document Type: Article

References (62)

1. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp. Biol. Med. 2003 228 : 1 14.
2. Digicaylioglu M, Bichet S, Marti HH et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc. Natl Acad. Sci. USA 1995 92 : 3717 20.
3. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 1998 52 : 235 49.
4. Rossert J, Eckardt KU. Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol. Dial. Transplant. 2005 20 : 1025 8.
5. Maier RF, Obladen M, Messinger D, Wardrop CA. Factors related to transfusion in very low birthweight infants treated with erythropoietin. Arch. Dis. Child Fetal Neonatal Ed. 1996 74 : F182 6.
6. Brown MS, Berman ER, Luckey D. Prediction of the need for transfusion during anemia of prematurity. J. Pediatr. 1990 116 : 773 8.
7. Widness JA, Seward VJ, Kromer IJ, Burmeister LF, Bell EF, Strauss RG. Changing patterns of red blood cell transfusion in very low birth weight infants. J. Pediatr. 1996 129 : 680 87.
8. Shannon K. Recombinant erythropoietin in anemia of prematurity: Five years later.[comment]. Pediatrics 1993 92 : 614 17.
9. Strauss RG. Erythropoietin and neonatal anemia. N. Engl. J. Med. 1994 330 : 1227 8.
10. Shannon KM. Anemia of prematurity: Progress and prospects. Am. J. Pediatr. Hematol. Oncol. 1990 12 : 14 20.
11. Carnielli V, Montini G, Da Riol R, Dall'Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J. Pediatr. 1992 121 : 98 102.
12. Obladen M, Sachsenweger M, Stahnke M. Blood sampling in very low birth weight infants receiving different levels of intensive care. Eur. J. Pediatr. 1988 147 : 399 404.
13. Brown MS, Garcia JF, Phibbs RH, Dallman PR. Decreased response of plasma immunoreactive erythropoietin to 'available oxygen' in anemia of prematurity. J. Pediatr. 1984 105 : 793 8.
14. Stockman JA III., Graeber JE, Clark DA, McClellan K, Garcia JF, Kavey RE. Anemia of prematurity: Determinants of the erythropoietin response. J. Pediatr. 1984 105 : 786 92.
15. Christensen RD. Recombinant erythropoietic growth factors as an alternative to erythrocyte transfusion for patients with 'anemia of prematurity'. Pediatrics 1989 83 : 793 6.
16. Dallman PR. Erythropoietin and the anemia of prematurity. J. Pediatr. 1984 105 : 756 7.
17. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: Developmental, nonlinearity, and treatment effects. J. Appl. Physiol. 1996 80 : 140 48.
18. Widness JA, Veng-Pedersen P, Modi NB, Schmidt RL, Chestnut DH. Developmental differences in erythropoietin pharmacokinetics: Increased clearance and distribution in fetal and neonatal sheep. J. Pharmacol. Exp. Ther. 1992 261 : 977 84.
19. Brown MS, Jones MA, Ohls RK, Christensen RD. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J. Pediatr. 1993 122 : 655 7.
20. Kling PJ, Widness JA, Guillery EN, Veng-Pedersen P, Peters C, DeAlarcon PA. Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant with renal failure. J. Pediatr. 1992 121 (5 Pt 1 822 5.
21. Gairdner D, Marks J, Roscoe JD. Blood formation in infancy. IV The early anemia of prematurity. Arch. Dis. Child. 1955 30 : 203 11.
22. Shannon KM, Naylor GS, Torkildson JC et al. Circulating erythroid progenitors in the anemia of prematurity. N. Engl. J. Med. 1987 317 : 728 33.
23. Rhondeau SM, Christensen RD, Ross MP, Rothstein G, Simmons MA. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the 'anemia of prematurity'. J. Pediatr. 1988 112 : 935 40.
24. Arif B, Ferhan K. Recombinant human erythropoietin therapy in low-birthweight preterm infants: A prospective controlled study. Pediatr. Int. 2005 47 : 67 71.
25. Maier RF, Obladen M, Scigalla P et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. N. Engl. J. Med. 1994 330 : 1173 8.
26. Shannon KM, Keith JF III., Mentzer WC et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995 95 : 1 8.
27. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial. J. Pediatr. 1995 126 : 421 6.
28. Meyer MP, Meyer JH, Commerford A et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study. Pediatrics 1994 93 (6 Pt 1 918 23.
29. Ohls RK, Ehrenkranz RA, Wright LL et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: A multicenter, randomized, controlled trial. Pediatrics 2001 108 : 934 42.
30. Shannon KM, Mentzer WC, Abels RI et al. Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study. J. Pediatr. 1991 118 : 949 55.
31. Obladen M, Maier R, Segerer H et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European Randomized Multicenter Trial. Contrib. Nephrol. 1991 88 : 314 26.
32. Halperin DS, Wacker P, Lacourt G et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. J. Pediatr. 1990 116 : 779 86.
33. Avent M, Cory BJ, Galpin J et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. J. Trop. Pediatr. 2002 48 : 227 33.
34. Wintour EM, Butkus A, Clemons G, Moritz K. Erythropoiesis and hemoglobin switching in the fetus and neonate. Proc. Aust. Physiol. Pharmacol. Soc. 1991 22 : 44 52.
35. Widness JA, Schmidt RL, Veng-Pedersen P, Modi NB, Sawyer ST. A sensitive and specific erythropoietin immunoprecipitation assay: Application to pharmacokinetic studies. J. Lab. Clin. Med. 1992 119 : 285 94.
36. Peters C, Georgieff MK, de Alarcon PA et al. Effect of chronic erythropoietin administration on plasma iron in newborn lambs. Biol. Neonate 1996 70 : 218 28.
37. Cutler DJ. Linear systems analysis in pharmacokinetics. J. Pharmacokinet. Biopharm. 1978 6 : 265 82.
38. Veng-Pedersen P. Noncompartmentally-based pharmacokinetic modeling. Adv. Drug. Deliv. Rev. 2001 48 : 265 300.
39. Akaike H. Automatic control: A new look at the statistical model identification. IEEE Trans. Contr. Theory 1974 19 : 716 23.
40. Veng-Pedersen P. Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J. Pharmacokinet. Biopharm. 1977 5 : 513 31.
41. Neelakantan S, Veng-Pedersen P. Determination of drug absorption rate in time-variant disposition by direct deconvolution using beta clearance correction and end-constrained non-parametric regression. Biopharm. Drug Dispos. 2005 26 : 353 70.
42. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following Busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway. J. Pharmacol. Exp. Ther. 2001 298 : 820 24.
43. Riley RS, Ben-Ezra JM, Tidwell A, Romagnoli G. Reticulocyte analysis by flow cytometry and other techniques. Hematol. Oncol. Clin. North Am. 2002 16 : 373 420.
44. Aulesa C, Ortega JJ, Ju JM et al. Flow cytometric reticulocyte quantification in the evaluation of hematologic recovery. Spanish Multicentric Study Group for Hematopoietic Recovery. Eur. J. Haematol. 1994 53 : 293 7.
45. Batjer J, Riddell K, Fritsma G. Predicting bone marrow transplant engraftment by automated flow cytometric reticulocyte analysis. Lab. Med. 1994 25 : 22 6.
46. Noronha JF, De Souza CA, Vigorito AC et al. Immature reticulocytes as an early predictor of engraftment in autologous and allogeneic bone marrow transplantation. Clin. Lab. Haematol. 2003 25 : 47 54.
47. Pradella M, Cavill I, d'Onofrio G. Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting. Clin. Lab. Haematol. 1996 18 (Suppl. 1 35 7.
48. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J. Pharmacol. Exp. Ther. 2000 295 : 346 51.
49. Finch CA, Harker LA, Cook JD. Kinetics of the formed elements of human blood. Blood 1977 50 : 699 707.
50. Hillman RS, Finch CA. Erythropoiesis: Normal and abnormal. Semin. Hematol. 1967 4 : 327 36.
51. Brugnara C. Reticulocyte cellular indices: A new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit. Rev. Clin. Lab. Sci. 2000 37 : 93 130.
52. Seip M. Reticulocyte studies. Acta Med. Scand. 1953 146 (Suppl. 282 1 164.
53. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol. Rev. 1992 72 : 449 89.
54. Heath CW, Daland GA. The life of reticulocytes. Experiments on their maturation. Arch. Intern. Med. 1930 46 : 533 51.
55. Haiden N, Cardona F, Schwindt J et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anemia of prematurity. Thromb. Haemost. 2005 93 : 118 23.
56. Reiter PD, Rosenberg AA, Valuck R, Novak K. Effect of short-term erythropoietin therapy in anemic premature infants. J. Perinatol. 2005 25 : 125 9.
57. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br. J. Clin. Pharmacol. 1990 29 : 709 13.
58. McMahon FG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990 76 : 1718 22.
59. Kampf D, Kahl A, Passlick J et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results. Contrib. Nephrol. 1989 76 : 106 10 discussion 10 1.
60. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol. Toxicol. 1990 66 : 83 6.
61. Hughes RT, Cotes PM, Oliver DO et al. Correction of the anaemia of chronic renal failure with erythropoietin: Pharmacokinetic studies in patients on haemodialysis and CAPD. Contrib. Nephrol. 1989 76 : 122 30.
62. Krishnan R, Shankaran S, Krishnan M, Kauffman RE, Kumar P, Lucena J. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants. Biol. Neonate 1996 70 : 135 40.